TAP-311 (TAP311) is a novel potent and selective CETP inhibitor with plasma IC50 of 62 nM.
TAP-311 displays >170-fold selectivity over CYPs, and has excellent pharmacokinetics in rats and robust efficacy in hamsters.
TAP-311 shows substantially reduced lipophilicity with only modest distribution into adipose tissue, and retains potency in hypertriglyceridemic plasma in vitro and in vivo.
TAP-311 does not increase blood pressure or plasma aldosterone levels in vivo, in contrast to torcetrapib (Cat# PC-42892).
